Role of methotrexate in the treatment of bullous pemphigoid in the elderly

Drugs and Aging

Volumn 25, Issue 8, 2008, Pages 623-629

  Patton, Timothy ^a   Korman, Neil ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bullous pemphigoid, treatment; Elderly; Methotrexate, therapeutic use

Indexed keywords

AZATHIOPRINE; BETAMETHASONE DIPROPIONATE; CLOBETASOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; FOLIC ACID; IMMUNOGLOBULIN; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PREDNISONE; RITUXIMAB; TETRACYCLINE;

AGED; ANEMIA; BONE MARROW SUPPRESSION; BULLOUS PEMPHIGOID; CATARACT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOPENIA; DIABETES MELLITUS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; GLAUCOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INFECTION; INTESTINE ULCER; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; MORNING DOSAGE; NAUSEA; OSTEOPOROSIS; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; SYSTEMIC THERAPY; TREATMENT INDICATION; VOMITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; HUMANS; METHOTREXATE; PEMPHIGOID, BULLOUS;

EID: 48249135163     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825080-00001     Document Type: Review

References (39)

1. Stanley JR, Hawley-Nelson P, Yuspa SH, et al. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 1981; 24 (3): 897-903
2. Labib RS, Anhalt GJ, Patel HP, et al. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol 1986; 136 (4): 1231-5
3. Liu Z, Giudice GJ, Swartz SJ, et al. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995; 95 (4): 1539-44
4. Korman NJ. Bullous pemphigoid: the latest in diagnosis, prognosis, and therapy. Arch Dermatol 1998; 134 (9): 1137-41
5. Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions: Bullous Diseases French Study Group. Arch Dermatol 1995; 131 (1): 48-52
6. Zillikens D, Wever S, Roth A, et al. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol 1995; 131 (8): 957-8
7. Adam BA. Bullous diseases in Malaysia: epidemiology and natural history. Int J Dermatol 1992; 31 (1): 42-5
8. Jin P, Shao C, Ye G. Chronic bullous dermatoses in China. Int J Dermatol 1993; 32 (2): 89-92
9. Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005; 141 (6): 691-8
10. Serwin AB, Bokiniec E, Piascik M, et al. Epidemiological and clinical analysis of pemphigoid patients in northeastern Poland in 2000-2005. Med Sci Monit 2007; 13 (8): CR360-4
11. Nanda A, Al-Saeid K, Al-Sabah H, et al. Clinicoepidemiological features and course of 43 cases of bullous pemphigoid in Kuwait. Clin Exp Dermatol 2006; 31 (3): 339-42
12. Haynes L, Swain SL, Cambier J, et al. Aging and immune function: summary of a workshop held at Trudeau Institute, Saranac Lake, NY. Mech Ageing Dev 2005; 126 (6-7): 822-5
13. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346 (5): 321-7
14. Patton T, Korman NJ. Bullous pemphigoid treatment review. Expert Opin Pharmacother 2006; 7 (17): 2403-11
15. Khumalo N, Kirtschig G, Middleton P, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2005; (3): CD002292
16. Menter MA, Krueger GC, Feldman SR, et al. Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. J Am Acad Dermatol 2003; 49 (2 Suppl.): S39-43
17. Baggott JE, Morgan SL, TS Ha, et al. Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheumatol 1993 Mar-Apr; 11 Suppl. 8: S101-5
18. Kazlow Stern D, Tripp JM, Ho VC, et al. The use of systemic immune moderators in dermatology: an update. Dermatol Clin 2005; 23 (2): 259-300
19. Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther 2007 Jul-Aug; 20 (4): 216-8
20. Downham 2nd TF, Chapel TA. Bullous pemphigoid: therapy in patients with and without diabetes mellitus. Arch Dermatol 1978; 114 (11): 1639-42
21. Paul MA, Jorizzo JL, Fleischer Jr AB, et al. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1994; 31 (4): 620-5
22. Bohm I, Bauer R. Treatment of bullous pemphigoid with low-dose methotrexate. Hautarzt 1997; 48 (12): 910-4
23. Heilborn JD, Stahle-Backdahl M, Albertioni F, et al. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1999; 40 (5 Pt 1): 741-9
24. Dereure O, Bessis D, Guillot B, et al. Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases. Arch Dermatol 2002; 138 (9): 1255-6
25. Bara C, Maillard H, Briand N, et al. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol 2003; 139 (11): 1506-7
26. Lovell DJ, Zaoutis TE, Sullivan K. Immunosuppressants, infection, and inflammation. Clin Immunol 2004; 113 (2): 137-9
27. Boey O, Van Hooland S, Woestenburg A, et al. Methotrexate should not be used for patients with end-stage kidney disease. Acta Clin Belg 2006; 61 (4): 166-9
28. Roenigk Jr HH, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998 Mar; 38 (3): 478-85
29. Grills C, Burge S. Methotrexate: improving safety profile. Australas J Dermatol 2006; 47 (3): 178-81
30. Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol 2005; 53 (4): 652-9
31. Rheumatrex® (methotrexate) [package insert]. Cranbury (NJ): STADA Pharmaceuticals, Inc., 2003
32. DeHoratio DM, Sperber BR, Werth VP. Glucocorticoids in the treatment of bullous diseases. Dermatologic Ther 2002; 15 (4): 298-310
33. Wise M, Callen JP. Azathioprine: a guide for the management of dermatology patients. Dermatol Ther 2007 Jul-Aug; 20 (4): 206-15
34. Sami N, Ali S, KC Bhol, et al. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 2003 Nov; 17 (6): 641-5
35. Schmidt E, Seitz CS, Benoit S, et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007; 156 (2): 352-6
36. Grattan CE. Evidence of an association between bullous pemphigoid and psoriasis. Br J Dermatol 1985; 113 (3): 281-3
37. Person JR, Rogers 3rd RS. Bullous pemphigoid and psoriasis: does subclinical bullous pemphigoid exist? Br J Dermatol 1976; 95 (5): 535-40
38. Stuttgen G, Bockendahl H, Remy W, et al. Psoriasis and bullous dermatoses. Hautarzt 1978; 29 (3): 134-40
39. Koerber Jr WA, Price NM, Watson W. Coexistent psoriasis and bullous pemphigoid: a report of six cases. Arch Dermatol 1978; 114 (11): 1643-6